Genscript Biotech Stock Performance
| GNNSF Stock | USD 2.31 0.19 8.96% |
Genscript Biotech holds a performance score of 14 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 0.75, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Genscript Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Genscript Biotech is expected to be smaller as well. Use Genscript Biotech treynor ratio, as well as the relationship between the rate of daily change and period momentum indicator , to analyze future returns on Genscript Biotech.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Genscript Biotech are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Genscript Biotech reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 629.1 M | |
| Total Cashflows From Investing Activities | -212.5 M |
Genscript |
Genscript Biotech Relative Risk vs. Return Landscape
If you would invest 130.00 in Genscript Biotech on April 26, 2025 and sell it today you would earn a total of 101.00 from holding Genscript Biotech or generate 77.69% return on investment over 90 days. Genscript Biotech is currently producing 1.0515% returns and takes up 5.7632% volatility of returns over 90 trading days. Put another way, 51% of traded pink sheets are less volatile than Genscript, and 79% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Genscript Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Genscript Biotech's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Genscript Biotech, and traders can use it to determine the average amount a Genscript Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1825
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | GNNSF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.76 actual daily | 51 51% of assets are less volatile |
Expected Return
| 1.05 actual daily | 21 79% of assets have higher returns |
Risk-Adjusted Return
| 0.18 actual daily | 14 86% of assets perform better |
Based on monthly moving average Genscript Biotech is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Genscript Biotech by adding it to a well-diversified portfolio.
Genscript Biotech Fundamentals Growth
Genscript Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Genscript Biotech, and Genscript Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genscript Pink Sheet performance.
| Return On Equity | -0.56 | |||
| Return On Asset | -0.12 | |||
| Profit Margin | (0.66) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | 5.11 B | |||
| Shares Outstanding | 2.12 B | |||
| Price To Earning | 200.00 X | |||
| Price To Book | 6.65 X | |||
| Price To Sales | 10.82 X | |||
| Revenue | 510.6 M | |||
| EBITDA | (494 M) | |||
| Cash And Equivalents | 1.26 B | |||
| Cash Per Share | 0.60 X | |||
| Total Debt | 121.07 M | |||
| Debt To Equity | 0.56 % | |||
| Book Value Per Share | 0.36 X | |||
| Cash Flow From Operations | (136.79 M) | |||
| Earnings Per Share | (0.17) X | |||
| Total Asset | 2.23 B | |||
About Genscript Biotech Performance
By analyzing Genscript Biotech's fundamental ratios, stakeholders can gain valuable insights into Genscript Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Genscript Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Genscript Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the Peoples Republic of China, Japan, the other Asia Pacific regions, and internationally. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the Peoples Republic of China. Genscript Biotech operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5573 people.Things to note about Genscript Biotech performance evaluation
Checking the ongoing alerts about Genscript Biotech for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Genscript Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Genscript Biotech is way too risky over 90 days horizon | |
| Genscript Biotech appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 510.6 M. Net Loss for the year was (347.87 M) with profit before overhead, payroll, taxes, and interest of 303.48 M. | |
| Genscript Biotech has accumulated about 1.26 B in cash with (136.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Roughly 38.0% of the company shares are held by company insiders |
- Analyzing Genscript Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Genscript Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Genscript Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Genscript Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Genscript Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Genscript Biotech's pink sheet. These opinions can provide insight into Genscript Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Genscript Pink Sheet analysis
When running Genscript Biotech's price analysis, check to measure Genscript Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genscript Biotech is operating at the current time. Most of Genscript Biotech's value examination focuses on studying past and present price action to predict the probability of Genscript Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genscript Biotech's price. Additionally, you may evaluate how the addition of Genscript Biotech to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |